Showing results (71-80 of 81) with videos related to
Sort By:
Pageof 9
Haematologica|May 20, 2021
Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopeniaKarina Althaus, Peter Möller, Günalp Uzun, et al.Nature Medicine|June 3, 2024
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL studyFranck Morschhauser, Saurabh Dahiya, M Lia Palomba, et al.Blood|January 29, 2021
A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHLNorbert Schmitz, Lorenz Truemper, Krimo Bouabdallah, et al.Blood Advances|December 11, 2024
Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World StudyEvgenii Shumilov, Rebecca Wurm-Kuczera, Andrea Kerkhoff, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2024
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma)Olivier Tournilhac, Bettina Altmann, Birte Friedrichs, et al.Blood Advances|April 16, 2025
Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphomaEvgenii Shumilov, Julia Katharina Scholz, Maximilian Seib, et al.Lancet (London, England)|December 24, 2019
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trialViola Poeschel, Gerhard Held, Marita Ziepert, et al.Nature Medicine|December 18, 2021
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trialNathan Hale Fowler, Michael Dickinson, Martin Dreyling, et al.Blood|January 9, 2024
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial updateMartin Dreyling, Nathan Hale Fowler, Michael Dickinson, et al.Hemasphere|July 10, 2023
Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER StudyLorenz Thurner, Marita Ziepert, Christian Berdel, et al.Pageof 9